601607 上海医药
2025/06 - 中期
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额989,2575,827,2585,231,5204,743,3615,061,326
投资活动产生之现金流量净额(1,240,266)415,980(2,491,873)(12,473,124)(6,015,576)
筹资活动产生之现金流量净额3,753,377(1,863,930)231,85112,138,5941,565,628
汇率变动对现金及现金等价物的影响(13,773)2,157(5,580)(12,440)(50,323)
现金及现金等价物净增加/(减少)3,488,5964,381,4642,965,9184,396,391561,055
期初现金及现金等价物余额31,881,27327,499,80924,533,89120,137,50019,576,445
期末现金及现金等价物余额35,369,86931,881,27327,499,80924,533,89120,137,500